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Abstract
Drug resistance is a rapidly emerging concern, thus prompting the development of novel
therapeutics or combinatorial therapy. Currently, combinatorial therapy targets are based
on knowledge of drug mode of action and/or resistance mechanisms, constraining the num-
ber of target proteins. Unbiased genome-wide screens could reveal novel genetic compo-
nents within interaction networks as potential targets in combination therapies. Testing this,
in the context of antimicrobial resistance, we implemented an unbiased genome-wide
screen, performed in Saccharomyces cerevisiae expressing a Candida glabrata PDR1+
gain-of-function allele. Gain-of-function mutations in this gene are the principal mediators of
fluconazole resistance in this human fungal pathogen. Eighteen synthetically lethal S. cere-
visiae genetic mutants were identified in cells expressing C. glabrata PDR1+. One mutant,
lacking the histone acetyltransferase Gcn5, was investigated further. Deletion or drug-medi-
ated inhibition of Gcn5 caused a lethal phenotype in C. glabrata cells expressing PDR1+
alleles. Moreover, deletion or drug-mediated inactivation of Gcn5, inhibited the emergence
of fluconazole-resistant C. glabrata isolates in evolution experiments. Thus, taken together,
the data generated in this study provides proof of concept that synthetically lethal genetic
screens can identify novel candidate proteins that when therapeutically targeted could allow
effective treatment of drug-resistant infections.
Author summary
Life threatening infections are an increasing reality. Multi-drug resistant bacteria e.g.
MRSA are present in nearly all hospitals, and community acquired TB is often recalcitrant
to treatment. Less well known, but causing four to five times more deaths in the UK than
MRSA, are fungi in the genus Candida. These are commonly associated with mucosal
infections such as “thrush”, but are responsible for> 400,000 life-threatening infections
worldwide every year, especially in the immunosuppressed patient population. One of the
principle pathogens is Candida glabrata. This fungus grows as a single celled yeast, and
alarmingly is highly resistant to both host innate defences and many clinically used anti-
fungal drugs. Even with the best possible medical care, infections with this yeast cause
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~50% mortality and alarmingly the incidence of C. glabrata infections is steadily climbing.
This demands that novel antifungal therapies are developed that can target drug resistant
fungal infections such as C. glabrata. We have identified genes that prevent the growth of
fungal cells that express gain-of-function mutations in Pdr1, a key mediator of antifungal
resistance in C. glabrata. We also provide proof of concept that targeting a protein essen-
tial for Pdr1 function significantly inhibits the emergence of antifungal drug resistance.
Thus such an approach could provide a powerful tool in developing treatments for drug
resistant infections.
Introduction
Drug resistance has emerged as a huge problem in many areas of medicine from cancer to
infectious diseases [1, 2, 3, 4]. This is leading to the development of novel therapeutic strate-
gies. Multi-target therapies are gaining ground, where combinations of drugs targeting differ-
ent components of disease networks are deployed with the expectation of reduced toxicity,
emergence of resistance, and off-target effects [5, 6, 7]. Combinatorial therapies involving an
antibiotic and a second drug either targeting the same pathway, another cellular function, and/
or specific mechanisms of antimicrobial drug resistance have shown promise as therapeutic
regimens to treat antimicrobial drug resistant infections [8]. A major impediment to this
approach is the characterization of the adjunctive targets. To date most adjunctive therapy tar-
gets have been selected based on previous biological knowledge of drug mode of action and/or
mechanisms of resistance. This severely constrains the number of proteins that can be targeted
for adjunctive therapy. In this study, we hypothesized that unbiased genome-wide screens can
reveal previously unknown proteins that could be targeted for adjunctive therapy. This has
recently been demonstrated in the context of cancer, where Cas9 mediated genome editing
was used to target chromatin regulatory domains in a murine acute myeloma cell line, identi-
fying six known drug targets, and a further 19 genes that are essential in this cancer cell line
[9]. In relation to antimicrobial resistant infection, we rationalised that the characterization of
mutations that genetically interact with alleles conferring drug resistance could reveal novel
proteins that could be therapeutically targeted to allow effective treatment of antimicrobial
drug resistant infections.
Fungi are important agents of infectious disease, causing more deaths annually than either
malaria or TB [10]. In this context, Candida species are the fourth most commonly isolated
species from nosocomial blood stream infections, causing life threatening disease in individu-
als with AIDs, patients recovering from surgical procedures or major burns, and those under-
going chemotherapy and organ transplant. Systemic fungal infections are currently very
difficult to diagnose, and even with best practice management mortality rates are generally
higher than for bacterial disease [11]. Furthermore, the effectiveness of the drugs used to treat
fungal infections is decreasing, as antifungal drug resistance is rapidly emerging. Antifungal
resistance has been reported in environmental fungal isolates suggesting a reservoir of resistant
strains [12,13]. There is an urgent clinical and economic need for new cost effective treatment
options, including novel therapeutics.
Candida glabrata ranks second after Candida albicans as the most common yeast pathogen
of humans. It is responsible for many opportunistic infections in immunocompromised indi-
viduals, which are associated with a high mortality rate. The incidence of C. glabrata infections
has grown rapidly over the last 20 years, and is responsible for ~25% of systemic candidiasis
cases [14,15]. The reason for this increasing incidence of C. glabrata infection is not fully
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understood, but it is well established that this species has a higher innate tolerance to com-
monly administered azole antifungals, in particular fluconazole (FLZ), the principle therapeu-
tic option for Candida infections. For instance, C. glabrata populations have an average MIC
to fluconazole (FLZ) of 4 μg/ml compared to 0.125 μg/ml for C. albicans populations [16–18].
Alarmingly, C. glabrata is also adept at rapidly acquiring drug resistance [19]. MIC values of
64 μg/ml are found in up to 30% of C. glabrata isolates, and thus are often resistant to FLZ
therapy [20,21].
One of the principle mediators of FLZ resistance and acquired resistance are gain of func-
tion mutations in the PDR1 (CAGL0A00451g) gene (PDR1+), which encodes a transcriptional
activator of genes encoding drug efflux pumps [22]. To date, many PDR1+ mutations have
been described that mediate azole resistance (Table 1). These PDR1+ mutations cause amino
acid changes across all four functional domains of the transcription factor: the transcriptional
activation domain, the regulatory domain, the middle homology region, and the activation
Table 1. PDR1 clinical isolates and location of gain-of-function mutation used in this study.
Clinical Isolate name PDR1 allele
DSY486 WT�
DSY489 L328F
DSY562 WT�
DSY565 L280F
DSY2253 WT�
DSY2254 D1082G
DSY529 WT�
DSY530 E1083Q
DSY738 WT�
DSY739 R376W
DSY726 WT�
DSY727 D876Y
DSY753 WT�
DSY754 Y584C
DSY2234 WT�
DSY2235 T607S
DSY3629 P822L
DSY2726 F853Q
DSY2746 I373V
DSY2725 Y285C
DSY1169 V785D
DSY1180 D1089Y
DSY2257 N691D
DSY2268 S316I
DSY1185 R592G
DSY2279 G583S
DSY2271 D261G
DSY2273 R293I
DSY756 S343F
DSY2315 R376G
DSY2277 R592S
� refers to the parental strain of gain-of-function mutations that arose after FLZ exposure.
https://doi.org/10.1371/journal.pgen.1008259.t001
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domain (Fig 1). PDR1 is up-regulated during systemic infections [23,24], and is induced in
response to combinatorial stresses encountered in vivo. C. glabrata strains harbouring PDR1+
mutations exhibit increased virulence [18] implying adaptation within the host to antifungals
may itself enhance the ability of C. glabrata to cause disease. In this study, we have performed
an unbiased genetic screen to identify mutants that are synthetically lethal with PDR1+ flucon-
azole resistant C. glabrata cells, having adopted the approach of a combination of genome-
wide screens [25] and mutant construction to identify C. glabrata loss of function mutations
that interact to impact negatively on the growth in combination of with specific FLZ resistant
alleles. We then used prior knowledge to identify which of the proteins encoded by these
genetic interactors can be targeted therapeutically, either using known or newly discovered
small molecule inhibitors, to treat FLZ resistant C. glabrata.
Mutations are termed ‘synthetically lethal’ if either mutation alone has no impact on cellular
viability, but in combination result in cellular death. Our hypothesis, was that by inhibiting the
product of a gene whose deletion is synthetically lethal with PDR1+ alleles will allow targeting
of FLZ resistant C. glabrata. To test this prediction we set to address two questions; what are
the synthetic lethal/synthetic sick interaction partners of PDR1+ alleles, and, as proof of con-
cept, can any of these be targeted to prevent the emergence of azole resistant C. glabrata?
Therefore the primary aim of this work is to identify pathways that could be targeted to pre-
vent the emergence of antifungal drug resistance. In this study we have taken this methodology
to identify conserved synthetic genetics interactions across a PDR1+ allele, then used this data
to identify small molecule inhibitors of these synthetic interactors (namely GCN5 inhibitor ɣ-
butyrolactone) and determined if they can be used to treat FLZ resistant C. glabrata.
Results & discussion
SDL-SGA screen of C. glabrata PDR1+
Synthetic Genetic Array (SGA) screening is not currently possible in C. glabrata, as the tech-
nique relies on high throughput mating. Hence to identify PDR1+ synthetic genetic interac-
tions, we used the model yeast S. cerevisiae as a surrogate with a view that key synthetic lethal
interactions would subsequently be confirmed in C.glabrata. To initiate the characterization of
C. glabrata PDR1+ synthetic genetic interaction network, we performed a synthetic dosage
lethal (SDL)-SGA experiment [26], to identify synthetic interactions with a PDR1+L280F allele
described in a clinical C. glabrata isolate DYS565 (Fig 2) [19,21]. This particular allele was cho-
sen due to its poor clinical outcomes and high FLZ MIC [27]. The DYS565 strain has a FLZ
MIC of 128 μg/ml and a G840C (L280F) mutation (PDR1+L280F), whereas the parental strain,
DYS562, obtained from the same patient is relatively FLZ sensitive (MIC 8 μg/ml) and con-
tains a wild-type PDR1 allele. The PDR1+L280F was amplified by PCR, sequence verified, cloned
and transformed into an S. cerevisiae MATa SGA starter strain, with the endogenous copy of
PDR1 deleted and then mated to the entire MATα knock-out collection. This genome-wide
Fig 1. Schematic of PDR1 (CAGL0A00451g). The 4 different domains are indicated by the dark grey boxes – DBD –
DNA binding domain; ID – inhibitory domain; MHR- middle homology region and AD – activation domain. Each of
the individual light grey and black vertical lines represents a PDR1 gain of function mutation that has been identified
in a clinical isolates resulting in resistance and/or tolerance to azoles.
https://doi.org/10.1371/journal.pgen.1008259.g001
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SGA screen was performed in triplicate and all double mutants were visually scored for growth.
A total of 144 negative genetic interactions were identified with the C. glabrata PDR1+L280F allele
(Fig 2, S1 Table), of which 22 were synthetically lethal (S2 Table) and the remainder caused sig-
nificant reductions in growth. Of the 22 synthetic lethal interactions four were also lethal with
wild-type PDR1 i.e. elp2, elp4, elp6 and pdr5. Elp2, Elp4 and Elp6 are all components of the elon-
gator complex, while Pdr5 is a multidrug transporter involved in pleiotropic drug responses.
Thus 18 strains had specific lethal interactions with C. glabrata PDR1+L280Fand included genes
with functions related to drug transport (ERG5, EAF1), and others transcription factors (e.g.
PDR3, PDR8, STE12 and UME6). In the case of the synthetic sick interactions identified in both
screens, CgPDR1 (104 interactions) and PDR1+L280F (105 interactions), 90 were common to
both screens with 14 unique to CgPDR1 and 15 unique to PDR1+L280F (S1 Table and Fig 2).
To determine if these genetic interactions were maintained with different PDR1+ gain of
function alleles, we performed tailored SGA screens. Specifically, the previous interactions
Fig 2. Genetic interaction network map of C. glabrata PDR1WT and PDR1L280F. Genome-wide synthetic interaction SGA screens were performed using query
strains expressing either the wild type or PDR1+L280F C. glarbata ORF. Genes are represented by nodes that are colour coded corresponding to their cellular roles
(www.yeastgenome.org and www.candidagenome.org) and/or assigned through review of the literature. Interactions are represented by edges. A comprehensive
list of all interactions can be found in the supplementary information.
https://doi.org/10.1371/journal.pgen.1008259.g002
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identified from the PDR1+L280F screen were sub-arrayed to determine if the synthetic lethal
interactions were common to other gain of function alleles. Four other gain-of-function alleles
were selected; S316I, L1391I, E555K and F817S, covering the four main functional domains of
Pdr1 (S3 Table, S1 Fig and Fig 1). From this refined screen, we were confident in following
GCN5 as our proof of principle gene of interest for chemical inhibition, due to its synthetically
lethal interaction with the additional gain of function mutants screens and when chemically
inhibited in a series of gain of function mutants we were able to induce lethality in the strains
(Fig 3).From these additional screens, we identified 9 SL interactions that were common to all
gain of function genes tested; DUG1, EA1, ELP4, GLC5, HEK2, PDR5, PDR8, STE12 and STE2.
These genes offer potential further targets for chemical inhibition in future studies, across a
variety of molecular functions. In S. cerevisiae GCN5 encodes a component of the ADA and
SAGA histone acetyltransferase complexes.
Deletion of GCN5 is synthetically lethal in C. glabrata PDR1+ cells
To test our hypothesis that drug targeting of lethal interactors, identified above, would abolish
survival of drug resistant PDR1+ cells, we focussed on GCN5 for two reasons. Firstly, deletion
of GCN5 was synthetically lethal with the five gain-of-function PDR1+ alleles tested and, sec-
ondly, there is a well-characterized specific inhibitor of the Gcn5 HAT, γ-butyrolactone. Thus,
if our hypothesis is correct, prevention of Gcn5 function through γ-butyrolactone treatment,
should kill C. glabrata cells harbouring the drug resistant PDR1+L280Fallele.
As a first step, we confirmed that expression of PDR1+L280F in a C. glabrata gcn5 null
mutant background was lethal (Fig 4). To achieve this PDR1+L280F was placed under the con-
trol of the methionine repressible promoter in pCU-MET3 [28] and transformed into a C.
glabrata gcn5 pdr1 double null mutant. The induction of PDR1+L280F in this strain resulted in a
loss of viability, thus confirming that the synthetic lethal interaction identified in S. cerevisiae
is conserved in C. glabrata.
Once we had confirmed that loss of Gcn5 function is lethal in C. glabrata cells expressing the
PDR1+L280F fluconazole resistant allele, we then determined the impact of chemically inhibiting
Fig 3. FLZ resistant clinical isolates of C. glabrata containing PDR1+ alleles are sensitive to ɣ-butyrolacetone. C.
glabrata FLZ resistant clinical isolates containing PDR1+ mutations were grown on synthetic complete (top panel) or
synthetic complete +2mM ɣ-butylroacetone (bottom panel). The ɣ-butylroacetone was synthetic lethal to 20/31 FLZ
resistant C. glabrata clinical isolates containing PDR1+ alleles. Plate layout showing which gain-of-function mutants
screened shown below the gel images.
https://doi.org/10.1371/journal.pgen.1008259.g003
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Gcn5. Notably, the addition of 2mM γ-butyrolactone, the chemical inhibitor of Gcn5, prevented
the growth of S. cerevisiae pdr1Δ strains expressing C. glabrata PDR1L280F, the clinical FLZ resis-
tant C. glabrata strain DYS565 expressing PDR1L280F, and an engineered C. glabrata lab strain
(BG2 derivative) in which the wild-type PDR1 allele was replaced with PDR1L280F (Fig 4). Col-
lectively, these data demonstrate that targeting Gcn5, a synthetically lethal interacting partner of
PDR1L280F identified in S. cerevisiae, renders both this species and the orthologous C. glabrata
mutant inviable, strongly supporting the proposition that targeting synthetic lethal interactions
offers a new paradigm for the treatment of drug resistant infection.
To further explore this concept, we investigated whether the addition of ɣ-butyrolactone
would prevent and/or inhibit the growth of addition FLZ-resistant clinical isolates with different
gain of function mutations in PDR1 (Table 1). Notably, ɣ-butyrolactone prevented the growth of
20/31 clinical isolates screened (Fig 4). This demonstrates that the chemical inactivation of the
Gcn5 protein is synthetically lethal in approximately 65% of the PDR1+ FLZ resistant alleles tested.
Does the deletion of synthetic lethal genes, or chemical inactivation of their
encoded proteins reduce the emergence of FLZ resistance in C. glabrata?
Finally, we examined whether targeting synthetic lethal interactions could minimise the emer-
gence of FLZ resistance utilising an experimental evolution approach [29]. Using such an
approach allowed for the observation of the impact of their deletion on the emergence of FLZ
Fig 4. Confirmation that expression of PDR1+L280F in C. glabrata gcn5Δ cells is synthetically lethal. A C. glabrata
gcn5 pdr1 strain was transformed with pCU-MET3 (A) or pCU-MET3 containing PDR1L280F (B) and cultured on
synthetic complete media (left panel) or synthetic complete media lacking methionine (right panel). Induction of
PDR1L280F is lethal in C. glabrata gcn5 cells thus confirming the synthetic lethal interaction identified in S. cerevisiae.
https://doi.org/10.1371/journal.pgen.1008259.g004
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resistance. C. glabrata wild-type and gcn5 null strains, together with wild-type cells in which
the function of Gcn5 was chemically inhibited, were exposed to doubling dilutions of FLZ and
the emergence of resistance monitored. Our working hypothesis was that FLZ resistance
would emerge at a much-reduced rate and to a lower level in strains that had synthetic lethal
genes deleted or chemically inactivated (in this case GCN5), compared to wild-type C.
glabrata.
As each propagation was made to the next round of selection, the PDR1 gene was
sequenced to determine in each condition, and at which cycle, gain of function mutations
started to arise in the populations and to what region of the gene they mapped to. For the wild
type strain BG2, after going through three rounds of exposure to FLZ and up to a concentra-
tion of 8μg/ml, we identified the appearance of the first gain of function mutation in the PDR1
allele (Fig 5A). This mutation was located in the activation domain of the gene. As the expo-
sure to FLZ continued for a further 7 cycles, there was a noted increase in the number of gain
Fig 5. Evolution of wildtype, gcn5 null and gcn5 chemically inhibited C. glabrata cells in the presence of fluconazole. C.
glabrata cells grown in increasing concentrations of FLZ, with the PDR1 gene sequenced after each round to determine when
and in which domain gain of function mutations are identified in. (A) Schematic of experiment. 10 individual flasks of C.
glabrata cells – wildtype, Δgcn5 and chemically inhibited Gcn5 were exposed to increased concentrations of FLZ. The flask
where inhibition of growth was first observed was used as the started culture for the subsequence round of drug exposure
until 10 rounds of drug exposure was completed. At each pitching of cells, PDR1 was sequenced to identified when a gain of
function mutation first emerged. (B) In wildtype C. glarbata cells, after 3 rounds of exposure to increasing FLZ
concentrations, PDR1 mutations were identified and mapped to the activation domain. (C) C. glabrata Δgcn5 cells, after 6
rounds of exposure to increasing FLZ concentrations, PDR1 gain of function mutations were isolated and mapped to the
activation domain and the middle homology domain. (D) C. glabrata cells that had Gcn5p chemically inhibited through with
the addition of ɣ-, after 7 rounds of exposure to increasing FLZ concentrations, the emergence of PDR1 gain of function
mutations was observed in the activation domain and DNA binding domain. The number of gain of function mutations
observed is dramatically reduced in both the Δgcn5 and chemically inhibited Gcn5 FLZ exposures.
https://doi.org/10.1371/journal.pgen.1008259.g005
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of function mutations arising in the wild type strain. This was also linked to the increase in
FLZ concentration. Following the 10 cycles of propagation in FLZ, we had identified 50 previ-
ously described gain of function mutations in PDR1 (Fig 5B).
In the case of the gcn5 null strain (Fig 5C), and the chemically inhibited gcn5 strain (Fig 5D), a
gain of function mutation was not observed in PDR1 until 7 rounds of propagation in FLZ. In the
gcn5 null mutant, the T2450C (F817S) mutation in the activation domain (Table 2) was the first
observed mutation, whereas T2575 (F859L) was the first mutation identified in the chemically
inhibited strain. From this data, it is possible to determine that the evolution of C. glabrata Δgcn5
mutants in the presence of FLZ inhibits the emergence of gain of function mutations in PDR1.
Concluding remarks
In this proof of concept study we have demonstrated that the identification of synthetic lethal
genetic interactions with alleles that confer antifungal drug resistance is a valuable approach to
identify pathways that could be targeted to prevent the emergence of drug resistance. By
employing SGA analysis we identified a number of genetic mutations that were synthetically
lethal with PDR1+ gain-of-function alleles. Focussing on one specific mutation, that in the his-
tone acetyltransferase Gcn5, we could show that deletion or chemical inactivation of Gcn5 sig-
nificantly inhibited the emergence of PDR1+ gain-of-function alleles in evolution experiments.
Histone modifications modulate the packing of chromatin, this level of packing is critical for
gene transcription, as the cellular machinery must have access to promoters to allow for tran-
scription. As previously stated GCN5 in S. cerevisiae is known to be a component of the ADA
and SGA complexes, therefore we propose that in C. glabrata clinical isolate with gain of func-
tion mutations in PDR1, it is acting as a gene silencer thus resulting in the synthetic lethal phe-
notype. The combination of the interaction between GCN5 and PDR1gain of function may be
resulting in the inhibition of histone acetyltransferases and DNA damage events resulting
from drug exposure leading to cell death. This control of chromatin remodelling processes
may provide a target for novel drug therapies. Future work employing similar genetic
approaches could be powerful in identifying additional targets that could halt the emergence
of drug resistant strains.
Table 2. Gain-of-function mutations in the activation domain of CgPDR1 observed during evolution in presence
of FLZ.
T2450C (F817S)
C2465T (P822L)
T2558C (F853S)
T2575C (F859L)
G2626T (D876Y)
G2827A (G943S)
T2837C (L946S)
T2842A (F948I)
A3229G (N1077D)
G3235A (G1079R)
G3236T (G1079V)
C3239T (T1080I)
A3245G (D1082G)
G3265T (D1089Y)
T3278C (L1093P)
G3296C (G1099A)
https://doi.org/10.1371/journal.pgen.1008259.t002
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Methods
Strain generation
PDR1 genes were PCR amplified from their relevant strains, wildtype from BG2 (i.e. no point
mutations) and DSY565, the clinical isolate containing the PDR1+ gain of function mutation
L280F. PCR products were sequence verified prior to cloning into the Gateway system. Final
destination plasmids were transformed into S. cerevisiae strain Y7092[30], using standard LiAc
transformation protocols[31].
Candida glabrata PDR1 synthetic genetic interaction screens
The deletion mutant array was manipulated using a Singer RoTor HAD (Singer Instruments).
For the genome wide PDR1 and PDR1+L280F synthetic genetic screens, the MATα query strain
Y7092 [30] was transformed with either pDEST426-ccdB-GPD-PDR1 or pDEST426-ccdB-
GPD- PDR1+L280F. The resulting query strains were mated to the entire MATa deletion mutant
array and the SGA methodology was used as previously described to maintain the plasmid
[26]. All genome-wide screens were performed in triplicate at 30˚C with growth visually
scored for lethality (SL), slow growth (synthetic sick SS) or suppression (SUP). Putative genetic
interactions were identified in a minimum of two out of three replicates. These putative inter-
actions were then confirmed in S. cerevisiae and C. glabrata. (Confirmed genetic interactions
are listed in Supporting information, Fig 2).
Confirmation in Candida glabrata
To confirm the SGA screens performed in S. cerevisiae, we recapitulated the SL phenotypes in
C. glabrata. The gcn5 pdr1 null mutant was generated using standard deletion protocol [29],
followed by transformation of the plasmid containing the PDR1 or PDR1+L280F under the con-
trol of the MET3 promoter [31].
Dot assays with FLZ and γ-butyrolactone
Dot assays were performed by spotting 5 μl of 10-fold serial dilutions (OD600 = 0.1, 0.01,
0.001, 0.0001) onto specified media, and sealed plates were incubated at 37˚C. All dot assay
experiments were repeated using three different isolates of each strain. FLZ at concentrations
16–64μg/ml and ɣ-butyrolactone at 2mM were used in screening plates.
Evolution of C. glabrata strains in the presence of fluconazole
To examine the effect of FLZ treatment on the genome of C. glabrata strains, we performed a
series of control evolution experiments. We took C. glabrata strains; BG2, Δgcn5, and chemi-
cally inhibited BG2, and inoculated into doubling dilution of FLZ from 0-256 μg/ml, in syn-
thetic complete medium at 37˚C for 24 hours. The culture at the highest FLZ dose with
obvious growth was used to propagate the next FLZ gradient. This was performed for ten
cycles with each strain being tested in ten technical replicates. The same workflow was fol-
lowed for the chemically inhibited gcn5 strain to determine the impact on the emergence of
resistance via the addition of γ-butyrolactone to the media. The chemical inhibitor was com-
bined with FLZ. For both experimental regimens the level of FLZ was inferred, for each strain,
as the concentration from which propagation was made to the next round of selection. The
driving hypothesis for this section of work was that FLZ resistance would emerge at a reduced
rate and to a lower level in the strains that have had gcn5 deleted or chemically inhibited com-
pared to wild-type C. glarbata.
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Supporting information
S1 Fig. Genetic interaction network map of C. glabrata gain-of-function alleles; L139I,
E555K, F817S and S316I. Genome-wide synthetic interaction SGA screens were performed
using query strains expressing PDR1+L139I, PDR1+E555K, PDR1+F817S or PDR1+S316I C. glarbata
ORFs. Genes are represented by nodes that are colour coded corresponding to their cellular
roles (www.yeastgenome.org and www.candidagenome.org) and/or assigned through review
of the literature. Interactions are represented by edges. A comprehensive list of all interactions
can be found in the supplementary S3 Table.
(TIFF)
S1 Table. Functional analysis of SGA screens for PDR1 WT and PDR1+L280F. A comprehen-
sive list of interactions from SGA screens for PDR1 wildtype and PDR1 gain-of-function
mutation L280F.
(XLSX)
S2 Table. SGA analysis for PDR1+L280F. A functional analysis of the genetic interactions for
PDR1+L280F. The interactions have been broken down into the separate phenotypic subsets of
synthetic lethal and synthetic sick interactions followed by a further breakdown of those
unique to the gain-of-function mutation L280F.
(XLSX)
S3 Table. Genetic interactions for L139I, E555K, F817S and S316I gain of function muta-
tions in C. glabrata. Breakdown of the genetic interactins for 4 different gain-of-function
mutations in C. glabrata, the interactions are characterised as either SL – synthicaly lethal or
SS – synthetically sick phenotype.
(XLSX)
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